On Wednesday, ImmunityBio, Inc. (NASDAQ: IBRX ) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC) .

Price Action: IBRX stock is up 18.6% at $2.835 at last check Thursday.

Read Next:

Photo via Shutterstock.

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.